Leerink Partners Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $46
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mani Foroohar initiates coverage on Neurogene (NASDAQ:NGNE) with an Outperform rating and a price target of $46.
April 29, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners initiated coverage on Neurogene with an Outperform rating and a price target of $46.
The initiation of coverage by Leerink Partners with an Outperform rating and a high price target suggests a strong positive outlook for Neurogene. This is likely to attract investor attention and could lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100